CommercialCoverageMedium impact
08.01.93f, Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
Independence Blue Cross·Neurology, Internal Medicine, Family Medicine +1 more·Medical Policy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
This policy updates coverage, medical necessity criteria, and billing codes for monoclonal antibodies used to treat Alzheimer's disease. The changes affect both reimbursement positions and general guidelines for these specialized treatments.
Action Required
Before January 1, 2026: Billing team must review updated medical necessity criteria for monoclonal antibody treatments for Alzheimer's disease. Update prior authorization workflows and billing system edits according to new coverage guidelines. Ensure providers are aware of any documentation requirements for these treatments to avoid claim denials.